A Novel Cell Death Pathway Induced by Galectin-1
Galectin-1 诱导的新型细胞死亡途径
基本信息
- 批准号:6370407
- 负责人:
- 金额:$ 25.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-01 至 2005-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Cell death is a critical regulatory
process in development, in homeostasis, and in disease. Many cell death
triggers have been identified, although little is known about many of the
molecular pathways that lead to cell death. Galectin-1, a member of a family of
evolutionarily ancient lectins, induces death of thymocytes and T-cells. In
mammals, galectin-1 is expressed in lymphoid tissues, at sites of inflammation,
and in some types of cancer. Galectin-1 has also been shown to be
immunosuppressive in several animal models of autoimmune disease. Galectin-1
induces cell death of transformed epithelial cells as well, so that galectin-1
mediated cell death may be a fundamental mechanism that regulates cell survival
in many tissues. Other galectin family members have pro- or anti-apoptotic
activities in different tissues, suggesting that different galectins may
cooperate to regulate cell death. The goal of this application is to
characterize the molecular mechanism of galectin-1 cell death, to understand
the interaction of galectin-1 with glycoprotein receptors on the cell surface,
and the downstream events that regulate cell death.
The Specific Aims are:
1. To define features of the T-cell surface receptors for galectin-l required
to transmit the death signal. CD7 and CD43 are glycoprotein receptors for
galectin-1. Features of the glycans and the polypeptides that are essential for
sending the death signal will be identified.
2. To examine how galectin-l binding to T-cells results in molecular
interactions to deliver the death signal. Galectin-1 binding results in a
unique pattern of receptor reorganization on the T-cell surface. We will
identify features of the receptors required for this interaction, and
investigate whether receptor reorganization is required for cell death. Effects
of galectin-1 on cytoskeletal linker proteins and on the actin cytoskeleton
will be characterized. To examine cell-cell interactions that govern T-cell
death, receptor reorganization during galectin-1 mediated binding of T-cells to
thymic stromal cells will be examined.
3. To characterize intracellular components that regulate the galectin-l cell
death pathway.
We will examine the roles of the protein kinase C and protein phosphatase
families of enzymes in regulating galectin1 cell death. We determine how
galectin-3 expression regulates T-cell susceptibility to galectin-1.
描述(由申请人提供):细胞死亡是一个关键的调节因素,
在发展过程中,在稳态中,在疾病中。许多细胞死亡
触发因素已经确定,尽管对许多
导致细胞死亡的分子途径。半乳糖凝集素-1,一个家庭的成员,
在进化上古老的凝集素,诱导胸腺细胞和T细胞的死亡。在
在哺乳动物中,半乳糖凝集素-1在淋巴组织中,在炎症部位,
和某些类型的癌症。半乳凝素-1也已被证明是
在几种自身免疫性疾病动物模型中的免疫抑制。半乳糖凝集素-1
也诱导转化的上皮细胞的细胞死亡,使得半乳糖凝集素-1
介导的细胞死亡可能是调节细胞存活的基本机制
在许多组织中。其他半乳糖凝集素家族成员具有促凋亡或抗凋亡作用。
在不同组织中的活性,表明不同的半乳糖凝集素可能
共同调节细胞死亡。此应用程序的目标是
描述半乳糖凝集素-1细胞死亡的分子机制,
半乳凝素-1与细胞表面糖蛋白受体的相互作用,
以及调节细胞死亡的下游事件。
具体目标是:
1.为了确定所需的半乳糖凝集素-l的T细胞表面受体的特征,
传送死亡信号CD 7和CD 43是糖蛋白受体,
半乳糖凝集素-1。聚糖和多肽的特征对于
发出死亡信号的人会被识别出来
2.为了检查半乳糖凝集素-I如何与T细胞结合导致分子免疫应答,
传递死亡信号半乳糖凝集素-1结合导致
T细胞表面受体重组的独特模式。我们将
识别这种相互作用所需的受体的特征,以及
研究细胞死亡是否需要受体重组。影响
半乳糖凝集素-1对细胞骨架连接蛋白和肌动蛋白细胞骨架的影响
将被定性。检查控制T细胞的细胞与细胞相互作用
死亡,半乳糖凝集素-1介导的T细胞与
检查胸腺基质细胞。
3.为了表征调节半乳糖凝集素-l细胞的细胞内组分,
死亡之路
我们将研究蛋白激酶C和蛋白磷酸酶的作用
在调节galectin 1细胞死亡的酶家族。我们决定如何
半乳糖凝集素-3表达调节T细胞对半乳糖凝集素-1的敏感性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linda G Baum其他文献
Linda G Baum的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Linda G Baum', 18)}}的其他基金
Regulation of inflammatory cell migration in asthma
哮喘炎症细胞迁移的调节
- 批准号:
8063630 - 财政年份:2010
- 资助金额:
$ 25.95万 - 项目类别:
Regulation of inflammatory cell migration in asthma
哮喘炎症细胞迁移的调节
- 批准号:
7911394 - 财政年份:2010
- 资助金额:
$ 25.95万 - 项目类别:
Overcoming tumor cell resistance to apoptosis with a natural product, GCS-100
用天然产物 GCS-100 克服肿瘤细胞对细胞凋亡的抵抗
- 批准号:
7821317 - 财政年份:2009
- 资助金额:
$ 25.95万 - 项目类别:
Overcoming tumor cell resistance to apoptosis with a natural product, GCS-100
用天然产物 GCS-100 克服肿瘤细胞对细胞凋亡的抵抗
- 批准号:
7640481 - 财政年份:2009
- 资助金额:
$ 25.95万 - 项目类别:
Nipah Virus Pathobiology and Effects on Innate Immunity
尼帕病毒病理学及其对先天免疫的影响
- 批准号:
7027741 - 财政年份:2005
- 资助金额:
$ 25.95万 - 项目类别:
Nipah Virus Pathobiology and Effects on Innate Immunity
尼帕病毒病理学及其对先天免疫的影响
- 批准号:
6915278 - 财政年份:2005
- 资助金额:
$ 25.95万 - 项目类别:
Nipah Virus Pathobiology and Effects on Innate Immunity
尼帕病毒病理学及其对先天免疫的影响
- 批准号:
7406028 - 财政年份:2005
- 资助金额:
$ 25.95万 - 项目类别:
Nipah Virus Pathobiology and Effects on Innate Immunity
尼帕病毒病理学及其对先天免疫的影响
- 批准号:
7214116 - 财政年份:2005
- 资助金额:
$ 25.95万 - 项目类别:
Nipah Virus Pathobiology and Effects on Innate Immunity
尼帕病毒病理学及其对先天免疫的影响
- 批准号:
7569493 - 财政年份:2005
- 资助金额:
$ 25.95万 - 项目类别:
A Novel Cell Death Pathway Induced by Galectin-1
Galectin-1 诱导的新型细胞死亡途径
- 批准号:
6753612 - 财政年份:1997
- 资助金额:
$ 25.95万 - 项目类别:
相似海外基金
The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
- 批准号:
DP240102905 - 财政年份:2024
- 资助金额:
$ 25.95万 - 项目类别:
Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23K28188 - 财政年份:2024
- 资助金额:
$ 25.95万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
- 批准号:
2339172 - 财政年份:2024
- 资助金额:
$ 25.95万 - 项目类别:
Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
- 批准号:
10577518 - 财政年份:2023
- 资助金额:
$ 25.95万 - 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23H03498 - 财政年份:2023
- 资助金额:
$ 25.95万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
- 批准号:
10676407 - 财政年份:2023
- 资助金额:
$ 25.95万 - 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
- 批准号:
22KK0277 - 财政年份:2023
- 资助金额:
$ 25.95万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
- 批准号:
10599584 - 财政年份:2023
- 资助金额:
$ 25.95万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10530023 - 财政年份:2022
- 资助金额:
$ 25.95万 - 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
- 批准号:
10684172 - 财政年份:2022
- 资助金额:
$ 25.95万 - 项目类别:














{{item.name}}会员




